论文部分内容阅读
本文观察32例2型糖尿病患者,随机分为瑞格列奈组(19例),A组;那格列奈组(13例),B组;进行为期4周的对照观察。结果纳入病例40例,完成病例32例,两组基础资料有可比性。两组治疗后空腹血糖和餐后2小时血糖均呈有意义的下降(P<0.05)。从下降幅度的百分率统计,瑞格列奈组下降幅度明显高于那格列奈组,但空腹血糖下降幅度两组差异无统计学意义;餐后2小时血糖,瑞格列奈组优于那格列奈组,有统计学意义(P<0.05)。治疗后胰岛素和C肽水平均明显高于治疗前,呈有意义的升高,但两组比较,除餐后2小时C肽升高幅度,瑞格列奈组优于那格列奈组(P<0.05)外,余均无统计学差异。两组观察期间无不良反应。
In this study, 32 patients with type 2 diabetes mellitus were randomly divided into repaglinide group (n = 19), group A; nateglinide group (n = 13), group B; Results included 40 cases, 32 cases completed, the two basic data are comparable. After treatment, fasting blood glucose and postprandial blood glucose 2 hours showed a significant decrease (P <0.05). From the percentage decline in the statistics, the decline of repaglinide group was significantly higher than that of nateglinide group, but the decline in fasting blood glucose was no significant difference between the two groups; 2 hours postprandial blood glucose, repaglinide group was better than that Glinna group, with statistical significance (P <0.05). After treatment, the levels of insulin and C-peptide were significantly higher than those before treatment, but the two groups were significantly higher than nateglinide group P <0.05), the remaining no significant difference. No adverse reactions were observed during the two groups.